---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-006887"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2022-03-22T23:59:59+00:00"
generated_at: "2026-06-26T21:01:47.397270+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Absci posts Q4 revenue $1.5M, net loss $25.2M; reveals AI antibody design breakthroughs, partners NVIDIA

## Summary
- Q4 2021 revenue $1.5M, net loss $25.2M vs $4.9M YoY; FY2021 net loss $101.0M vs $14.4M.
- Cash of $279.9M; expects ~$120M net cash burn in 2022 (incl. ~$10.5M restricted cash).
- Announced ML models predicting antibody affinity across 4 orders of magnitude and naturalness scoring.
- Formed research collaboration with NVIDIA to scale in-silico drug discovery on A100 GPUs.
- Entered Merck collaboration for Bionic Enzyme; projected 8 active programs in 2022.

## SEC filing metadata
- accession: 0001628280-22-006887
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2022-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828022006887/0001628280-22-006887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828022006887/absc-20220322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-006887
- JSON: https://secwatch.observer/filing/0001628280-22-006887.json
- Plain text: https://secwatch.observer/filing/0001628280-22-006887.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.